KalVista Pharmaceuticals (NASDAQ: KALV) received a "buy" rating from Needham & Company with a target price of $32.00.
KalVista Pharmaceuticals (NASDAQ: KALV) received a "buy" rating from Needham & Company with a target price of $32.00, following a Q3 earnings report showing an EPS of ($0.87), surpassing estimates. The company, with a market cap of $513.02 million, has seen insider selling and mixed institutional investment activities. HC Wainwright also maintains a buy rating with a $20 target, while Cantor Fitzgerald upgraded it to strong-buy.
4 months ago
4 Articles
Further Reading
You have 9 free stories remaining this month. Subscribe anytime for unlimited access.